Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: Biomarker analyses of the CATCH trial

Journal of Clinical Oncology

Volumn 35, Issue 10, 2017, Pages 1078-1085

  Khorana, Alok A ^a   Kamphuisen, Pieter W ^b,c   Meyer, Guy ^d   Bauersachs, Rupert ^e,f   Janas, Mette S ^g   Jarner, Mikala F ^g   Lee, Agnes Y Y ^h,i  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Tergooi Hospitals   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e Darmstadt Hospital   (Germany)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g LEO PHARMA A S   (Denmark)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; PADGEM PROTEIN; THROMBOPLASTIN; TINZAPARIN; TUMOR MARKER; WARFARIN; BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; ASIAN; BLACK PERSON; CARDIOVASCULAR RISK; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSESSMENT; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE GENITAL TRACT CANCER; HEMATOLOGIC MALIGNANCY; HEPATOBILIARY SYSTEM CANCER; HIGH RISK POPULATION; HISPANIC; HUMAN; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SOLID TUMOR; UROGENITAL TRACT CANCER; VENOUS THROMBOEMBOLISM; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; METABOLISM; NEOPLASMS; PREDICTIVE VALUE; RISK FACTOR; TIME FACTOR;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; FACTOR VIII; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; P-SELECTIN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; THROMBOPLASTIN; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 85016605041     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.4564     Document Type: Article

References (30)

1. Khorana AA: Venous thromboembolism and prognosis in cancer. Thromb Res 125:490-493, 2010
2. Khorana AA, Francis CW, Culakova E, et al: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632-634, 2007
3. Sørensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000
4. Khorana AA, Kuderer NM, Culakova E, et al: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111: 4902-4907, 2008
5. Ay C, Dunkler D, Marosi C, et al: Prediction of venous thromboembolism in cancer patients. Blood 116:5377-5382, 2010
6. Kyrle PA: Predicting recurrent venous thromboembolism in cancer: Is it possible? Thromb Res 133:S17-S22, 2014 (suppl 2)
7. Louzada ML, Carrier M, Lazo-Langner A, et al: Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 126:448-454, 2012
8. den Exter PL, Kooiman J, Huisman MV: Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. J Thromb Haemost 11:998-1000, 2013
9. Ahn S, Lim KS, Lee YS, et al: Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: The Ottawa score. Support Care Cancer 21:2309-2313, 2013
10. Lyman GH, Bohlke K, Khorana AA, et al: Venous thromboembolismprophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 33:654-656, 2015
11. Lee AYY, Kamphuisen PW, Meyer G, et al: Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA 314:677-686, 2015
12. Lee AY, Levine MN, Baker RI, et al: Lowmolecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349: 146-153, 2003
13. Schulman S, Zondag M, Linkins L, et al: Recurrent venous thromboembolism in anticoagulated patients with cancer: Management and short-term prognosis. J Thromb Haemost 13:1010-1018, 2015
14. Khorana AA, Francis CW, Menzies KE, et al: Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 6:1983-1985, 2008
15. Zwicker JI, Liebman HA, Bauer KA, et al: Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: A randomizedcontrolled phase II trial (the Microtec study). Br J Haematol 160:530-537, 2013
16. Thaler J, Ay C, Mackman N, et al: Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 10:1363-1370, 2012
17. Bharthuar A, Khorana AA, Hutson A, et al: Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 132:180-184, 2013
18. Khorana AA, Connolly GC: Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27:4839-4847, 2009
19. Ay C, Vormittag R, Dunkler D, et al: D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27:4124-4129, 2009
20. Lee AY, Bauersachs R, Janas MS, et al: CATCH: A randomised clinical trial comparing longterm tinzaparin versuswarfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 13:284, 2013
21. R&D Systems: Human coagulation factor III/tissue factor Quantikine ELISA. https://www. rndsystems.com/products/human-coagulation-factoriii-tissue-factor-quantikine-elisa-dcf300#product-details
22. Wang JG, Geddings JE, Aleman MM, et al: Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 119: 5543-5552, 2012
23. Thomas GM, Brill A, Mezouar S, et al: Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. J Thromb Haemost 13:1310-1319, 2015
24. Khorana AA, Ahrendt SA, Ryan CK, et al: Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 13: 2870-2875, 2007
25. Zwicker JI, Liebman HA, Neuberg D, et al: Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15:6830-6840, 2009
26. Tatsumi K, Antoniak S, Monroe DM III, et al: Evaluation of a new commercial assay to measure microparticle tissue factor activity in plasma: Communication from the SSC of the ISTH. J Thromb Haemost 12:1932-1934, 2014
27. Kroger K,Weiland D, Ose C, et al: Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 17:297-303, 2006
28. Kanz R, Vukovich T, Vormittag R, et al: Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 9: 57-63, 2011
29. Srikanthan A, Tran B, BeausoleilM, et al: Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol 33:582-587, 2015
30. Khorana AA, McCrae K, Milentijevic D, et al: Current practice patterns and patient persistence on anticoagulant treatments for cancer-associated thrombosis. Blood 126:626, 2015